Skip to main content
. 2015 Feb;27(1):74–82. doi: 10.3978/j.issn.1000-9604.2015.01.02

Figure 3.

Figure 3

Immunoreactivity of DTPA-trastuzumab-IRDye 800 and [111In]-DTPA-trastuzumab-IRDye 800. (A) Cytofluorimetric comparison of unconjugated trastuzumab (red line), DTPA-trastuzumab (blue line), and DTPA-trastuzumab-IRDye 800 (brown line). The fluorescence intensity is presented as an overlay plot for identical antibody concentrations. The green line represents a negative control using nonspecific polyclonal human immunoglobulin; (B) Lindmo assay to determine immunoreactivity of [111In]-DTPA-trastuzumab-IRDye 800. By extrapolating a straight line to the intercept with the ordinate, the fraction of immunoreactive antibody is determined as the inverse of the intercept value (1/1.22=0.82).